TIMP1 and colonic neoplasm: Linear regression slopes of their dose–response curves (shown in Table 1 and Additional file 1: Figure S1) were close to zero for breast cancer, colon cancer, hepatocellular carcinoma, and lung cancer, indicating that serum TIMP-1 had little or no UEA fucosylation in these cancer conditions.